Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

327 ARTÍCULOS , VIENDO DEL 106 AL 120

Nanotechnology and Alzheimer's disease: what has been done and what to do

Ruozi B, Belletti D, Pederzoli F, Veratti P, Forni F, Vandelli MA, Tosi G.

Curr Med Chem. 2014;21(36):4169-85. doi: 10.2174/0929867321666140716100056.

The value of biomarker comparisons between autosomal dominant and late-onset Alzheimer disease

Fleisher AS.

JAMA Neurol. 2014 Sep;71(9):1087-8. doi: 10.1001/jamaneurol.2014.1747.

Patients' diagnosis decisions in Alzheimer's disease: the influence of family factors

Rapp T.

Soc Sci Med. 2014 Oct;118:9-16. doi: 10.1016/j.socscimed.2014.07.052. Epub 2014 Jul 24.

Retinal manifestations of Alzheimer's disease

Dehabadi MH, Davis BM, Wong TK, Cordeiro MF.

Neurodegener Dis Manag. 2014;4(3):241-52. doi: 10.2217/nmt.14.19.

Behavioral and psychological symptoms in Alzheimer's disease

Li XL, Hu N, Tan MS, Yu JT, Tan L.

Biomed Res Int. 2014;2014:927804. doi: 10.1155/2014/927804. Epub 2014 Jul 15.

MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research

Zimmer ER, Parent MJ, Cuello AC, Gauthier S, Rosa-Neto P.

Trends Neurosci. 2014 Nov;37(11):629-41. doi: 10.1016/j.tins.2014.07.002. Epub 2014 Aug 20.

Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease

Wierenga CE, Hays CC, Zlatar ZZ.

J Alzheimers Dis. 2014;42 Suppl 4(Suppl 4):S411-9. doi: 10.3233/JAD-141467.

The impact of illiteracy on the assessment of cognition and dementia: a critical issue in the developing countries

Noroozian M, Shakiba A, Iran-nejad S.

Int Psychogeriatr. 2014 Dec;26(12):2051-60. doi: 10.1017/S1041610214001707. Epub 2014 Aug 28.

Is cognitive training an effective treatment for preclinical and early Alzheimer's disease?

Gates NJ, Sachdev P.

J Alzheimers Dis. 2014;42 Suppl 4:S551-9. doi: 10.3233/JAD-141302.

Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease

Arai H, Ichimiya Y, Shibata N, Nakajima T, Sudoh S, Tokuda T, Sujaku T, Yokokawa S, Hoshii N, Noguchi H, Bille A.

Psychogeriatrics. 2014 Sep;14(3):165-74. doi: 10.1111/psyg.12055. Epub 2014 Sep 3.

Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias

Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, Corneveaux JJ, Hardy J, Vonsattel JP, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, Kamboh MI, Kofler JK, Mash DC, Duque L, Gilbert JR, Gwirtsman H, Buxbaum JD, Kramer P, Dickson DW, Farrer LA, Frosch MP, Ghetti B, Haines JL, Hyman BT, Kukull WA, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Reiman EM; Alzheimer's Disease Genetics Consortium (ADGC); Schellenberg GD, Montine TJ.

PLoS Genet. 2014 Sep 4;10(9):e1004606. doi: 10.1371/journal.pgen.1004606. eCollection 2014 Sep.

Detecting early preclinical Alzheimer's disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing

Belleville S, Fouquet C, Duchesne S, Collins DL, Hudon C.

J Alzheimers Dis. 2014;42 Suppl 4:S375-82. doi: 10.3233/JAD-141470.

Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease

Wattmo C, Londos E, Minthon L.

BMC Neurol. 2014 Sep 10;14:173. doi: 10.1186/s12883-014-0173-4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias